NCT02367196 is a Phase 1 clinical trial of CC-90002 in Hematologic Neoplasms, sponsored by Celgene.

Who is sponsoring NCT02367196?

NCT02367196 is sponsored by Celgene.

What drugs are being tested in NCT02367196?

Interventions in NCT02367196: CC-90002, Rituximab.

What condition does NCT02367196 study?

NCT02367196 studies Hematologic Neoplasms.

Is NCT02367196 still recruiting?

NCT02367196 is currently completed. Last updated 12 August 2021.

Last reviewed 2021-08-12 · How we verify

NCT02367196

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers

Completed Phase 1 Last updated 12 August 2021

What this trial tests

Phase 1 trial testing CC-90002 in Hematologic Neoplasms in 60 participants. Completed in 24 December 2020.

Timeline

12 March 2015

Primary endpoint
24 December 2020

24 December 2020

Quick facts

Lead sponsor	Celgene
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	12 March 2015
Primary completion	24 December 2020
Estimated completion	24 December 2020
Sites	13 locations across United States, Spain

Drugs / interventions tested

CC-90002 — full drug profile →
Rituximab — full drug profile →

Conditions studied

Hematologic Neoplasms — all drugs for Hematologic Neoplasms →

Sponsor

Celgene — full company profile →

Who can join

18 and older, any sex, with Hematologic Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CC-90002-ST -001 is an open-label, Phase 1, dose escalation clinical study in subjects with advanced, refractory solid and hematologic cancers.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Phagocytosis checkpoints as new targets for cancer immunotherapy.
Feng M, Jiang W, Kim BYS, Zhang CC, et al · · 2019 · cited 729× · PMID 31462760 · DOI 10.1038/s41568-019-0183-z
Targeting macrophages in cancer immunotherapy.
Duan Z, Luo Y. · · 2021 · cited 462× · PMID 33767177 · DOI 10.1038/s41392-021-00506-6
The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment.
Kim SK, Cho SW. · · 2022 · cited 300× · PMID 35685630 · DOI 10.3389/fphar.2022.868695
Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer.
Li C, Xu X, Wei S, Jiang P, et al · · 2021 · cited 259× · PMID 33504575 · DOI 10.1136/jitc-2020-001341
Targeting CD47 for cancer immunotherapy.
Jiang Z, Sun H, Yu J, Tian W, et al · · 2021 · cited 254× · PMID 34717705 · DOI 10.1186/s13045-021-01197-w
Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses.
Anfray C, Ummarino A, Andón FT, Allavena P. · · 2019 · cited 222× · PMID 31878087 · DOI 10.3390/cells9010046
Injury mechanisms in acute intracerebral hemorrhage.
Wilkinson DA, Pandey AS, Thompson BG, Keep RF, et al · · 2018 · cited 205× · PMID 28947377 · DOI 10.1016/j.neuropharm.2017.09.033
Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 "Don't Eat Me" Signals.
McCracken MN, Cha AC, Weissman IL. · · 2015 · cited 182× · PMID 26116271 · DOI 10.1158/1078-0432.ccr-14-2520

Verify or expand the search:

Other trials of CC-90002

Trials testing the same drug.

NCT02641002 — A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) · Phase 1 · terminated

Other recruiting trials for Hematologic Neoplasms

Currently open trials in the same condition.

NCT07519811 — LLM-Generated Plain-Language Patient Synopses to Improve Comprehension in Hematology and Oncology (oncOPAL) · NA · recruiting
NCT07485855 — Influenza Vaccination Strategy for Patients With Hematologic Malignancy · Phase 3 · recruiting
NCT07162038 — Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA- · Phase 1 · recruiting
NCT06685848 — Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion · NA · recruiting
NCT06433349 — A Multi-center Investigation of Family Health. · recruiting

Other Celgene trials

Trials by the same sponsor.

NCT07242781 — A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult M · Phase 1 · recruiting
NCT06988488 — A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide · Phase 1, PHASE2 · recruiting
NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
NCT06808984 — Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants W · Phase 2 · recruiting
NCT06782490 — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spastici · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02367196 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Celgene
Last refreshed: 12 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02367196.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing